The recently developed histological scoring system for NAFLD by the NASH Clinical Research Network (NASH CRN) is becoming increasingly popular. However, its generalizability to a community setting has not been evaluated.

Scoring systems to evaluate NAFLD/NASH include the Brunt system, the NASH Clinical Research Network (NASH CRN) system, and the SAF scoring system. Each system provides a grade based upon the degree of steatosis, lobular/portal inflammation, and ballooning degeneration, as well as a stage based upon the degree of fibrosis.

The Nonalcoholic Steatohepatitis Research Network was established by the NIDDK in response to the lack of clear understanding of the pathogenesis of NASH, its natural history, prognostic features, and treatment. The primary objective of the NASH CRN is to pursue clinical research on adult and pediatric NASH.

The NASH Clinical Research Network (NASH CRN) is a cooperative network of eight clinical centers and one Data Coordinating Center (DCC). Clinical centers are responsible for proposing study protocols, participating in their overall development, recruiting patients, conducting the research, and disseminating research findings.

Nonalcoholic steatohepatitis (NASH) is the progressive form of NAFLD. The Pathology Committee of the NASH Clinical Research Network designed and validated a histological feature scoring system that addresses the full spectrum of lesions of NAFLD and proposed a NAFLD activity score (NAS) for use in clinical trials.

The Clinical Research Network in Nonalcoholic Steatohepatitis (NASH) is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to focus on the etiology, contributing factors, natural history, complications, and therapy of …

Non-alcoholic fatty liver disease (NAFLD) which is defined as the accumulation of fat >5% of liver weight is increasingly becoming an important cause of chronic liver disease. This article...

非酒精性脂肪性肝病 (NAFLD)是一种与胰岛素抵抗和遗传易感密切相关的代谢应激性肝损伤，疾病谱包括非酒精性肝脂肪变、非酒精性脂肪性肝炎 (NASH)、肝硬化和肝细胞癌。 已经有治疗NASH的多种新药临床试验处于早期临床研究阶段，但到目前为止，很多被寄予厚望的药物在2期和3期未达到预期的疗效终点，因此从NASH新药治疗的临床研发和临床试验的实施仍然面临巨大挑战。 目前NASH新药治疗的主要治疗靶点包括：法尼酯X受体 (FXR)、成纤维细胞生长因子 …

In this review article we summarize various risk and etiological factors, diagnostic techniques, and therapeutic evaluation of pharmacological agents developed for MAFLD. Effective pharmaceutical...

Download scientific diagram | NASH CRN Scoring System: NAS and Fibrosis Score from publication: Frequency of non-alcoholic fatty liver disease in a series of forensic cases in Mexico |...